| Value | ₹0.81 Cr |
|---|
BSE filing, NSE: TRIMURTHI. Summary written from the filing by ALFA Finder's alert engine.
Novelix Pharmaceuticals Ltd: key numbers
- Share price
- ₹61.41
- Market cap
- ₹108.2 Cr
- Revenue (annual)
- ₹132.3 Cr
- Net profit (annual)
- ₹2.56 Cr
- P/E (TTM)
- 29.8×Sector 61.5×
- Promoter holding
- 54.29%+3.72% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novelix Pharmaceuticals Ltd
All →Novelix Pharmaceuticals Other Announcement
Novelix Pharmaceuticals Ltd has filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Novelix Pharmaceuticals Management Change
Novelix Pharmaceuticals announced the appointment of Mr. Gnana Prakash Gattu as Whole Time Director, approved by shareholders at the company's 32nd Annual General Meeting.
Novelix Pharmaceuticals Annual General Meeting
Novelix Pharmaceuticals held its 32nd Annual General Meeting on 30th September, 2026, transacting ordinary and special business items via e-voting and video conferencing.
Novelix Pharmaceuticals Other Announcement
Novelix Pharmaceuticals informs shareholders that the Annual Report for FY 2025-26 and the 32nd AGM notice are available on the Company's website.
Novelix Pharmaceuticals Annual Report
Novelix Pharmaceuticals filed its Annual Report and AGM Notice for the financial year 2025-26. The 32nd Annual General Meeting is scheduled for September 30, 2026.
Novelix Pharmaceuticals Annual General Meeting
Novelix Pharmaceuticals Limited will hold its 32nd Annual General Meeting on September 30, 2026. The company has fixed September 23, 2026, as the cut-off date for e-voting.
Other debt & borrowing announcements
All →Fusion CX Debt & Borrowing: ₹21.85 Cr
Fusion CX lent up to Rs.21.85 Crore (USD 2.3 million) to wholly owned subsidiary Fusion BPO Services. Terms: 8.5% interest, three-year tenure, unsecured.
- Value
- ₹21.85 Cr
- Execution
- 3 years from the date of disbursal
Fusion CX Debt & Borrowing
Fusion CX Limited executed an unsecured inter-corporate term loan at 8.5% p.a. for three years with its wholly owned subsidiary Fusion BPO Services Ltd, a related party. Amount is not stated in the filing.
- Execution
- 3 years from the date of disbursal
Spandana Sphoorty Financial Debt & Borrowing: ₹0.49 Cr
Spandana paid ₹0.49 Crore of quarterly interest on its secured NCDs on 27 October 2026. The coupon rate is 10.75% on a ₹50 Crore issue.
- Value
- ₹0.49 Cr
Mangalam Worldwide Debt & Borrowing: ₹1.14 Cr
Mangalam Worldwide paid Rs. 1.14 Crore interest on its NCDs (ISIN INE0JYY07026) on 28 October 2026, net of TDS. The company confirmed timely payment under Regulation 57.
- Value
- ₹1.14 Cr
Lloyds Metals & Energy Debt & Borrowing: ₹12,370 Cr
Lloyds Metals allotted 1,300 debt securities worth about ₹12,370 Crore on 29 October 2026. Three-year coupon is SOFR plus 450 bps, secured by Virtus Lloyds share pledges.
- Value
- ₹12,370 Cr
- Execution
- 3 years
Lloyds Metals & Energy Debt & Borrowing: ₹1,235 Cr
Lloyds Metals' committee approved terms for USD 130 million senior secured notes, about Rs.1,235 Crore. The notes mature in October 2029 at SOFR plus 450 bps.
- Value
- ₹1,235 Cr